PAI-1 secreted from metastatic ovarian cancer cells triggers the tumor-promoting role of the mesothelium in a feedback loop to accelerate peritoneal dissemination.
Animals
Cell Line, Tumor
Cell Movement
Chemokine CXCL5
/ metabolism
Coculture Techniques
Culture Media, Conditioned
/ metabolism
Epithelium
/ metabolism
Feedback, Physiological
Female
Humans
Interleukin-8
/ metabolism
Mice
NF-kappa B
/ metabolism
Ovarian Neoplasms
/ genetics
Paracrine Communication
Peritoneal Neoplasms
/ genetics
Plasminogen Activator Inhibitor 1
/ genetics
Signal Transduction
Tumor Microenvironment
Cancer-associated mesothelial cells
Microenvironment
Ovarian cancer
Peritoneal metastasis
Plasminogen activator inhibitor-1
Journal
Cancer letters
ISSN: 1872-7980
Titre abrégé: Cancer Lett
Pays: Ireland
ID NLM: 7600053
Informations de publication
Date de publication:
01 02 2019
01 02 2019
Historique:
received:
29
04
2018
revised:
01
10
2018
accepted:
16
10
2018
pubmed:
16
11
2018
medline:
5
11
2019
entrez:
16
11
2018
Statut:
ppublish
Résumé
The mesothelium, covered by a continuous monolayer of mesothelial cells, is the first protective barrier against metastatic ovarian cancer. However, mesothelial cells release tumor-promoting factors that accelerate the process of peritoneal metastasis. We identified cancer-associated mesothelial cells (CAMs) that had tumor-promoting potential. Here, we found that plasminogen activator inhibitor-1 (PAI-1) induced the formation of CAMs, after which CAMs increasingly secreted the oncogenic factors interleukin-8 (IL-8) and C-X-C motif chemokine ligand 5 (CXCL5), further promoting the metastasis of ovarian cancer cells in a feedback loop. After the formation of CAMs, PAI-1 activated the nuclear factor kappa B (NFκB) pathway in the CAMs, thus transcriptionally upregulating the expression of the downstream NFκB targets IL-8 and CXCL5. Moreover, PAI-1 correlated with peritoneal metastasis in ovarian cancer patients and indicated a poor prognosis. In both ex vivo and in vivo models, after PAI-1 expression was knocked down, the metastasis of ovarian cancer cells decreased significantly. Therefore, targeting PAI-1 may provide a potential target for future therapeutics to prevent the formation of CAMs and alleviate peritoneal metastasis in ovarian cancer patients.
Identifiants
pubmed: 30429105
pii: S0304-3835(18)30641-4
doi: 10.1016/j.canlet.2018.10.027
pii:
doi:
Substances chimiques
CXCL5 protein, human
0
CXCL8 protein, human
0
Chemokine CXCL5
0
Culture Media, Conditioned
0
Interleukin-8
0
NF-kappa B
0
Plasminogen Activator Inhibitor 1
0
SERPINE1 protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
181-192Informations de copyright
Copyright © 2018 Elsevier B.V. All rights reserved.